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http://dx.doi.org/10.1016/j.ccell.2015.02.004SUMMARYNF-kB is a critical link between inflammation and cancer, but whether long non-coding RNAs (lncRNAs) regu-
late its activation remains unknown. Here, we identify an NF-KappaB Interacting LncRNA (NKILA), which is
upregulated by NF-kB, binds to NF-kB/IkB, and directly masks phosphorylation motifs of IkB, thereby inhib-
iting IKK-induced IkB phosphorylation and NF-kB activation. Unlike DNA that is dissociated from NF-kB by
IkB, NKILA interacts with NF-kB/IkB to form a stable complex. Importantly, NKILA is essential to prevent
over-activation of NF-kB pathway in inflammation-stimulated breast epithelial cells. Furthermore, low NKILA
expression is associated with breast cancer metastasis and poor patient prognosis. Therefore, lncRNAs
can directly interact with functional domains of signaling proteins, serving as a class of NF-kB modulators
to suppress cancer metastasis.INTRODUCTION
Nuclear factor-kB (NF-kB) is a family of transcription factors that
play critical roles in inflammation, immunity, cell proliferation,
differentiation, and survival (Ruland, 2011). Aberrant NF-kB
activation, a consequence of underlying inflammation in tumor
microenvironment that can promote cancer invasion and metas-
tasis, has been observed in many tumors, including breast can-
cer (Chaturvedi et al., 2011; Fornier et al., 2007). Hence, NF-kB is
considered as a critical link between inflammation and cancer. A
number of negative regulators, including regulatory proteins and
miRNAs, inhibit overactivation of NF-kB signaling and function
as tumor suppressors (Chaturvedi et al., 2011; Ruland, 2011).
Among them, IkB (inhibitor of NF-kB) that binds to and seques-Significance
Emerging evidences indicate that long non-coding RNAs (lncRN
lncRNAs play a role in cancer-associated inflammation is not k
that regulates NF-kB signaling and represses cancer-associate
hibits NF-kB signaling by masking the phosphorylation sites
expression is significantly decreased in many breast cancers, w
prognosis. Our study has discovered a class of lncRNAs that
370 Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc.ters NF-kB in the cytoplasm is considered as a major brake on
NF-kB signaling. IkB kinases (IKK), which can be activated by
various stimuli, can phosphorylate IkB, leading to its degradation
and subsequent NF-kB activation. However, previous studies
have shown that elevated IKK activity induced by inflammatory
stimuli persists much longer than NF-kB activation (Ojha et al.,
2008) and basal IKK activity is also sufficient to phosphorylate
NF-kB-bound IkB (O’Dea et al., 2008), suggesting that some un-
known mechanisms may protect NF-kB-bound IkB from being
phosphorylated by the persistently elevated or basal IKK activity.
Long non-coding RNAs (lncRNAs) are a large class of non-pro-
tein-coding transcripts that are greater than 200 bases in length
and are involved in numerous physiological and pathological
processes (Wang and Chang, 2011). Presently, only a smallAs) regulate various hallmarks of cancer. However, whether
nown yet. Here we report that NKILA is an essential lncRNA
d inflammation. NKILA binds to NF-kB/IkB complex and in-
of IkB and stabilizing the complex. Nevertheless, NKILA
hich is associated with cancer metastasis and poor patient
directly regulate signaling pathways.
number of lncRNAs have been characterized functionally, and
most of them are shown to control gene expression by regulating
various aspects of gene expression (Anko¨ and Neugebauer,
2010; Carrieri et al., 2012; Gong and Maquat, 2011; Hung
et al., 2011; Lee, 2012; Wang et al., 2011; Yoon et al., 2012).
Many lncRNAs are shown to regulate important cancer hall-
marks, including proliferation (Yang et al., 2013b), apoptosis
(Huarte et al., 2010), metastasis (Gupta et al., 2010; Yang
et al., 2013a; Yuan et al., 2014), metabolism (Yang et al., 2014),
senescence (Yap et al., 2010), and drug-resistance (Fan et al.,
2014). Nevertheless, whether lncRNA plays a role in cancer-
related inflammation is not clear yet.
Although the precise mechanisms by which lncRNAs function
remain poorly understood, a widely proposed model is that
lncRNAs may play their role via discrete modules that decoy,
guide, or scaffold other regulatory proteins (Guttman and Rinn,
2012; Wang and Chang, 2011). The ‘‘guiding’’ lncRNAs, like
KCNQ1OT1 (Pandey et al., 2008) and lincRNA-p21 (Huarte
et al., 2010), are associated with transcriptional co-regulators
or chromatin regulatory protein complexes and recruit them to
specific genomic DNA regions to regulate transcription. Addi-
tionally, ‘‘decoying’’ lncRNAs, such as GAS5 (Kino et al., 2010),
Lethe (Rapicavoli et al., 2013), and PANDA (Hung et al., 2011),
mimic and compete with their consensus DNA binding motifs
for binding nuclear receptors or transcription factors in the
nuclei, or act as decoy microRNA binding sites like ceRNAs to
control the functions of regulatory miRNAs (Salmena et al.,
2011). Furthermore, lncRNAs can serve as molecular scaffolds,
bringing specific regulatory proteins into proximity with each
other to function as a unique complex, such as HOTAIR (Tsai
et al., 2010), XIST (Jeon and Lee, 2011), and NRON (Sharma
et al., 2011). Collectively, these studies indicate that the function
of most lncRNAs depends on their ability to interact with pro-
teins, implying that lncRNAs may also directly interact with func-
tional domains of signaling proteins and thus regulate signal
transduction. Indeed, it has recently been reported that a lncRNA
regulates STAT6 signal transduction by interacting with STAT6 in
the cytoplasm of dendritic cells and modulating its phosphoryla-
tion (Wang et al., 2014). However, it remains unclear whether
lncRNAs can regulate NF-kB activation by interacting with and
post-translationally modifying NF-kB signaling proteins.
Because it is widely accepted in the field of NF-kB that IkB can
rapidly dissociate NF-kB from its cognate DNA and a stable
NF-kB:IkBa:DNA complex is unlikely to form (Zabel and
Baeuerle, 1990), whether lncRNA can interact with NF-kB in
the presence of IkB needs mechanistic investigation. In this
study, we aimed to investigate the contributions of lncRNAs in
NF-kB signaling pathway of breast cancer cells and their roles
in breast cancer metastasis.
RESULTS
NKILA Is an lncRNA Upregulated by Inflammatory
Cytokines via NF-kB Signaling
Aberrant NF-kB activation underlies the development of many
cancers (Chaturvedi et al., 2011). Inflammatory cytokines abun-
dant in breast cancer, including tumor necrosis factor (TNF)-a
and IL-1b, have been shown to activate NF-kB signaling in tumor
cells (Chaturvedi et al., 2011; Goldberg and Schwertfeger, 2010).To investigate the role of lncRNA in this process, we usedmicro-
array to establish lncRNA expression profiles in MDA-MB-231
breast cancer cells treated by these cytokines. A classical NF-
kB activator, lipopolysaccharide (LPS), was also used. We found
that 23 lncRNAs were upregulated and 28 lncRNAs downregu-
lated by all the above stimuli by more than 10-fold (Table S1).
Among them, NKILA, a lncRNA encoded by a gene at chromo-
some 20q13, was consistently found upregulated by more than
12-fold. Northern blotting and quantitative RT-PCR (qRT-PCR)
confirmed the significantly increased NKILA expression in both
MDA-MB-231 and MCF7 breast cancer lines (Figure 1A and
Figure S1A). We also estimated the number of NKILA RNA
molecules per MCF7 cell by Northern blotting (Figure S1B) and
absolute quantitative PCR (Figure S1C and Table S2). The
expression level of NKILA in MCF7 cells was similar to Gas5 in
HeLa cells (Kino et al., 2010). The result also showed TNF-a
treatment upregulated NKILA copy number by 5.8-fold (Figures
S1B and S1C and Table S2). Using 50- and 30- rapid amplification
of cDNA ends, NKILA was found to be a 2,570 nucleotide (nt) in-
tronless transcript that is identical to AK056098 in GeneBank or
uc002xyu in the UCSC database. Apart from a few short poten-
tial open reading frames (ORF) that have limited chance (<1%) of
encoding short ORF encoded polypeptides (Slavoff et al., 2013),
NKILA does not have a typical protein-coding ORF that is longer
than 300 nt. Confocal microscopy for fluorescent in situ hybrid-
ization (FISH) showed that NKILA located primarily in the cyto-
plasm (Figure 1B), which was confirmed by nuclear/cytoplasm
fractionation (data not shown), suggesting that NKILA may exert
its biological function in the cytoplasm.
We then investigated whether NF-kB signaling is responsible
for the induced NKILA transcription. Sc-3060 and JSH-23,
two inhibitors for NF-kB nuclear translocation, abrogated the
stimuli-induced NKILA upregulation in MDA-MB-231 cells (Fig-
ure 1C). Further, a constitutively active IKKb (CA-IKK2) (Huber
et al., 2004) in MDA-MB-231 cells induced NF-kB activation
and upregulated NKILA expression, which could be completely
inhibited by Sc-3060 or JSH-23 (Figure 1D). Using a series of
pGL3 reporter plasmids containing deleted (Figure S1D) or
mutated (Figure 1E) 50-flanking region of NKILA, we identified a
kB binding site located at 104 to 95 bp upstream of NKILA
TSS (Figure S1D). This was further confirmed by chromatin
immunoprecipitation (ChIP) analysis with anti-p65 antibody (Fig-
ure 1F) and electrophoretic mobility shift assay (EMSA) using a
biotin-labeled DNA probe containing the kB site of NKILA pro-
moter (Figure S1E).
NKILA Is a Negative Regulator of NF-kB Signaling
Because elevated NF-kB activity is associated with enhanced
invasiveness of tumor cells (Huber et al., 2004), we examined
the correlation between NKILA expression and basal NF-kB ac-
tivities in nine breast cancer cell lines with different metastatic
potentials. Surprisingly, NKILA expression was much higher in
the five low-metastatic breast cancer lines, including MCF7,
ZR-75-1, T47D, MDA-MB-453, and BT-474 with low NF-kB ac-
tivities, than in three high-metastatic lines, including BT-549,
MDA-MB-436, and MDA-MB-231 with high NF-kB activities,
and SK-BR-3 line with moderate NF-kB activity (Figure 2A and
Figure S2A). These data indicate a negative correlation between
NKILA expression and NF-kB activity. Exogenous NKILACancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc. 371
Figure 1. Inflammatory Cytokines Upregu-
late NKILA via NF-kB Signaling
(A) Expression of NKILA in MDA-MB-231 and
MCF7 cells treated with inflammatory mediators
for 24 hr, assayed by Northern blotting.
(B) Confocal FISH images showing cytoplasmic
localization of NKILA in MDA-MB-231 and MCF7
cells. AS, probe for antisense NKILA; U6, probe for
U6 snRNA.
(C) Expression of NKILA assayed by qRT-PCR in
MDA-MB-231 cells induced by inflammatory
stimuli (mean ± SD, n = 3, **p < 0.01, versus
DMSO), with or without NF-kB inhibition by sc-
3060 or JSH-23 (JSH).
(D) Expression of NKILA assayed by qRT-PCR in
MDA-MB-231 cells with or without NF-kB inhibi-
tion by sc-3060 or JSH-23 (JSH) (mean ± SD, n = 3,
***p < 0.001, versus vec, ###p < 0.001, versus
DMSO).
(E) Luciferase reporter assays for HEK293 cells
transfected with reporter plasmids containing
NKILA promoter and treated with PBS or cyto-
kines for 24 hr (mean ± SD, n = 8, **p < 0.01, versus
wt; wt: wild-type 2,000+1 construct, mut:
2,000+1 construct with point mutation in kB
binding site).
(F) Localization of p65 to NKILA promoter, IkBa
promoter (positive control), or ACTB promoter
(negative control) in MDA-MB-231 cells treated
with TNF-a for 30 min with or without NF-kB inhi-
bition, analyzed by ChIP (mean ± SD, n = 3, **p <
0.01 versus PBS, ##p < 0.01 versus DMSO).
Treatment for 30 min was chosen due to optimal
p65 nuclear translocation.
See also Figure S1 and Table S1 and Table S2.(Figure S1F) in MDA-MB-231 cells reduced the basal activity by
60%,while silencing NKILA (Figure S1G) inMCF7 cells increased
NF-kB activity by 3- to 4-fold (Figure 2B and Figure S2B).
Furthermore, NKILA inhibited TNF-a-induced p65 nuclear trans-
location in MDA-MB-231 cells, while silencing NKILA signifi-
cantly prolonged p65 translocation to 24 hr (Figure 2C). TNF-
a-enhanced NF-kB transcriptional activity in MDA-MB-231 cells
was suppressed by 80% in cells with exogenous NKILA, but was
further increased by 3-fold upon NKILA silencing (Figure 2D).
Additionally, NKILA inhibited TNF-a-induced expression of
several NF-kB target genes (Figure S2C). Collectively, these
data suggest that NKILA acts as a negative regulator to suppress
both the basal and cytokine-stimulated NF-kB activities in breast
cancer cells.
To understand what leads to low NKILA expression and high
NF-kB activity in metastatic breast cancer cells, we monitored
the kinetics of NKILA expression after TNF-a treatment. NKILA
expression in MDA-MB-231 cells peaked at 12 hr after TNF-a
treatment, but dropped rapidly to baseline at 48 hr. In contrast,
NKILA expression in MCF7 cells plateaued at 12–24 hr after
TNF-a treatment and remained high for up to 72 hr (Figure 2E).
The half-life of NKILA is much shorter in MDA-MB-231
(3.8 hr) than in MCF7 cells (8.8 hr) upon transcriptional inhibi-
tion by a-amanitin (Figure 2F), indicating that NKILA is decaying
more rapidly in the former. It is known that miRNAs may degrade
mRNAs with poly A tails via a miRNA-directed deadenylation
pathway (Huntzinger and Izaurralde, 2011) and NKILA is such372 Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc.an adenylated RNA. Therefore, we explored whether NKILA is
degraded by specific miRNAs in high-metastatic breast cancer
cells. By screening a comprehensive library of 434 miRNAs pre-
dicted to target NKILA by RegRNA (Huang et al., 2006) (Table
S3), we identified seven miRNAs that markedly inhibited NKILA
expression in MCF7 cells with a Z score <3 (Figure S2D).
Among them, miR-103 and miR-107 displayed an opposite
expression pattern versus NKILA, as their levels were much
higher in high-metastatic than low-metastatic breast cancer cells
(Figure S2E), which is consistent with a previous report (Martello
et al., 2010). More importantly, antisense oligonucleotides for
miR-103 or miR-107 increased NKILA expression in MDA-MB-
231 cells by 3-fold, while mimics of miR-103 or miR-107 reduced
NKILA expression in MCF7 cells by 80% (Figure 2G), which
could be restored by silencing key mediators for miRNA-medi-
ated RNA degradation, including Argonaute protein EIF2C2
and GW182 protein TRNC6A (Huntzinger and Izaurralde, 2011)
(Figure S2F). Indeed, a miR-103/107 target site was found at
1,203–1,234 nt of NKILA (Figure S2G). Furthermore, luciferase
reporter assay using pMIR-REPORT constructs showed that
co-transfection of miR-103 or miR-107 significantly reduced
luciferase activity of the reporter gene cloned with wild-type
but not mutant miR-103/107 target sequence at its 30-UTR (Fig-
ure S2H). Therefore, overexpression of miR-103 and miR-107 in
high-metastatic breast cancer cells is responsible for rapid
degradation of NKILA, which offsets the enhanced transcription
of NKILA caused by high NF-kB activity.
Figure 2. NKILA Is a Negative Regulator of NF-kB Signaling
(A) NKILA expressions and basal NF-kB activities in various breast cancer cell
lines, shown by Northern blotting (NB) and EMSA.
(B) NF-kB activities of MDA-MB-231 cells stably expressing exogenous NKILA
or MCF7 cells expressing NKILA shRNAs, examined by EMSA. (vec, pcDNA
3.1 vector; AS, antisense NKILA; shvec, pMKO.1-puro shRNA vector; shGFP,
GFP-shRNA; shNK1, 2, NKILA-shRNA1, 2).
(C) p65 nuclear translocation in MDA-MB-231 expressing NKILA or NKILA
shRNA treated with TNF-a, assayed by immunofluorescent confocal micro-
scopy.
(D) NF-kB activity of TNF-a-treated MDA-MB-231 cells, examined by lucif-
erase reporter assay (mean ± SD, n = 8, ***p < 0.001 versus PBS, ##p < 0.01
versus vec, &&p < 0.01 versus shvec).
(E and F) NKILA expression kinetics in MCF7 andMDA-MB-231 cells following
TNF-a stimulation without (E) or with subsequent a-amanitin treatment (F).
(G) NKILA expression in MDA-MB-231 cells transfected with miR-103/107
antisense oligonucleotides (ASO) or in MCF7 cells transfected with miR-103/
107mimics, examined by qRT-PCR (mean ± SD, n = 3, **p < 0.01, ***p < 0.001,
###p < 0.001 versus mock).
See also Figure S2 and Table S3.
Figure 3. NKILA Inhibits IkB Phosphorylation by Interacting with the
NF-kB:IkB Complex
(A) Western blotting showing total and phosphorylated IKK and IkBa in MDA-
MB-231 or MCF7.
(B) Western blotting showing total and phosphorylated proteins of IKK and
IkBa in TNF-a-treated MDA-MB-231 cells.
(C) Confocal FISH images showing colocalization of NKILA and p65 in MCF7.
(D) Binding of NKILA to p65/p50/IkBa complex in MCF7 cells, shown by RNA
immunoprecipitation and qRT-PCR (mean ± SD, n = 3, **p < 0.01, ***p < 0.001
versus IgG).
(E) In vitro interaction between NKILA and p65, p50, or IkBa, shown by RNA
pulldown.
(F) Western blot analysis for phosphorylated and total IkBa in NKILA-ex-
pressing MDA-MB-231 cells treated with TNF-a and transfected with siRNAs
targeting p65 (GFP-si, GFP siRNA; p65-si1, 2, p65 siRNA1, 2).
See also Figure S3.NKILA Inhibits IkB Phosphorylation by Interacting with
the NF-kB:IkB Complex
To study the mechanisms by which NKILA suppresses NF-kB
activation, we examined the effect of NKILA on the phosphoryla-
tion of IkBa and IkB kinase (IKK). IkBa phosphorylation was in-
hibited in MDA-MB-231 cells by ectopic NKILA expression, but
was enhanced inMCF7 cells by silencing NKILA. However, basal
IKK phosphorylation was not influenced by altering NKILA in
both cell lines (Figure 3A). Furthermore, enforcing or silencingNKILA expression in MDA-MB-231 cells reduced or increased
TNF-a-induced IkBa phosphorylation respectively, but did not
influence IKK phosphorylation (Figure 3B), suggesting that
NKILA mainly affects IkBa phosphorylation but not IKK activa-
tion. Inhibiting IKK kinase activity by Bay-117082 or Wedelolac-
tone abolished the effects of NKILA-shRNA on IkBa phosphory-
lation and NF-kB activation (Figures S3A and S3B), indicating
that IKK is upstream of NKILA in the pathway. Furthermore,
silencing NKILA had no effect on NF-kB activation in cells with
trans-dominant IkBa (TD-IkBa) (Huber et al., 2004) or with IkBa
silenced (Figure S3C). These results suggest that NKILA sup-
presses NF-kB activation by inhibiting IKK-induced IkBa phos-
phorylation without influencing IKK activity.
The cytoplasmic localization of NKILA implies that the lncRNA
may function by interacting with cytoplasmic NF-kB:IkBcom-
plex. Indeed, confocal microscopy for NKILA FISH and p65Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc. 373
Figure 4. NKILA Stably Associates with the NF-kB:IkB Complex via
Two Motifs
(A) In vitro interaction of sequentially deleted NKILA mutants with p65 alone or
p65/p50/IkBa (NF-kB/IkBa) complex, assayed by RNA pulldown.
(B) Interaction of NKILA truncation mutants with p65/p50 alone or in the
presence of IkBa, assayed by RNA pulldown (NK, full-length NKILA; NK322–359,
NKILA truncation mutant containing nt 322–359; NK286–402, nt286–402;
NK286–444, nt286–444; NK286–562, nt286–562).
(C) RNA EMSA determining interaction of NK286–402 (left) or NK286–444 (right)
with NF-kB (p65/p50 heterodimer) and IkBa. (NF-kB:IkBa indicates the molar
ratio between p65/p50 heterodimer and IkBa.)
(D) RNA pulldown showing effects of mutations of hairpin A (NK286–444mA) or
hairpin B (NK286–444mB) in NK286–444 on its binding capacity to p65/p50 alone or
in presence of IkBa. (NF-kB:IkBa indicates molar ratio.)
(E) RNA pulldown showing effects of mutations of hairpin A (NK286–444mA) or
hairpin B (NK286–444mB) in NK286–444 on its binding capacity to p65/p50 alone or
in presence of IkBa.
See also Figure S4 and Table S4.immunostaining showed80%co-localization of NKILA and p65
in the cytoplasm of MCF7 cells (Figure 3C and Figure S3D).
Immunoprecipitation (IP) of p65, p50, or IkBa, but not IKKb, spe-
cifically retrieved NKILA (Figure 3D). Silencing p65 eliminated
NKILA retrieval by p50 or IkBa, but silencing p50 or IkBa did
not reduce NKILA enrichment in p65 immunoprecipitates (Fig-
ure S3E), suggesting that NKILA has strong affinity to p65, but
not to p50 or IkBa. This was confirmed by retrieval of p65, p50,
and IkBawith biotinylatedNKILA fromMCF7only in the presence
of p65 (Figure S3F). In vitro RNA/protein interaction assay also
showed that NKILA binds to p65, but not p50 or IkBa, and NKILA
can only retrieve p50 or IkBa from complexes containing p65
(Figure 3E). Furthermore, silencing p65 abolished the inhibitory
effect of NKILA on TNF-a-induced IkBa phosphorylation (Fig-
ure 3F). These results suggest that NKILA binds p65 to associate
with NF-kB:IkBa complex, which is essential for its function.
NKILA Binds to p65 at Two Different Sites to Stably
Associate with the NF-kB:IkB Complex
Nevertheless, it has been shown that IkBa can rapidly dissociate
the complex of NF-kB transcription factor from its cognate DNA374 Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc.(Zabel and Baeuerle, 1990). Thus, it is generally assumed that
an NF-kB:IkBa:DNA complex is unlikely to be stable, although
such a transient NF-kB:IkBa:DNA complex was demonstrated
recently (Sue et al., 2011). Therefore, we investigated howNKILA
binds to p65 in the presence of IkBa to form a stable NF-kB:Ik
Ba:NKILA complex. A series of NKILA deletion mutants was
used to determine the nucleotides in NKILA that binds to p65
in the presence or absence of IkBa. NKILA mutants retaining nt
300–500 bound to p65 alone or p65:p50:IkBa complex as effi-
ciently as full-length NKILA, whereas other mutants completely
lost their binding capacity (Figure 4A), suggesting that nt
300–500 of NKILA is responsible for the association with
p65:p50:IkBa complex via p65. Two independent sets of soft-
ware, Mfold (Zuker, 2003) and RNAfold (Hofacker, 2003), pre-
dicted two hairpin structures within nt 300–500, named hairpin
A (nt 322–359) and hairpin B (nt 395–418), respectively (Fig-
ure S4A). Hairpin A, analogous to NF-kB binding DNA motif
(NBM), is formed by two NF-kB binding consensus sequences
(nt 322–332 and nt 350–359 of NKILA) that fold back to comple-
ment with each other (Table S4). Both hairpin structures were
confirmed by RNA structure probing (Figure S4B).
EMSA using a 30-biotin-labeled RNA probe containing
hairpin A, (nt 322–359, NK322–359) revealed an RNA:p65 complex
that was super-shifted by anti-p65 antibody and competed by a
non-labeled consensus kB-bindingDNAprobe (Figure S4C), indi-
cating that hairpin A mimics NBM and binds to NF-kB. Addition-
ally, the hairpin probe also formed complexwith c-rel, but notwith
p50 (Figure S4C). Therefore, hairpin A at nucleotides 322 to 359 of
NKILAmimics kBbindingmotif and binds toNF-kB. To determine
if hairpin A binds to NF-kB in vivo, we generated a hairpin A
(NK322–359) tagged with a fragmented GFP mRNA (162–278 nt
of NC_011521.1) and transfected it into MDA-MB-231 cells.
RNA-IP using anti-p65 antibody showed that NF-kB p65 binds
to the tagged hairpin A, but not the tagged hairpin A mutated at
nt 331 and its complementary nt 351 (Table S4 and Figure S4D).
To further evaluate how hairpins A and B contribute to p65
binding in the presence of IkBa, we used another series of dele-
tion mutants predicted to preserve secondary structure of hair-
pins. Mutants retaining only hairpin A, nt 322–359 (NK322–359)
and nt 286–402 (NK286–402), bound to the p65:p50 heterodimer,
as well as the p65 homodimer in the absence of IkBa, but not
in the presence of IkBa. Nevertheless, mutants retaining both
hairpins, nt 286–444 (NK286–444) and nt 286–562 (NK286–562),
bound to both the p65:p50 and the p65:p50:IkBa complexes
as efficiently as full-length NKILA (Figure 4B). This was confirmed
by EMSAs using NK286–402 harboring hairpin A or NK286–444
harboring both hairpins (Figure 4C). Consistent with previous
findings of NF-kB-binding DNA motif (Zabel and Baeuerle,
1990), IkBa can dissociate the RNA:NF-kB complex with hairpin
A alone. Nevertheless, RNA:NF-kB complex with both hairpin A
and B was not dissociated by IkBa, but instead formed a com-
plex with IkBa, suggesting that hairpin B of NKILA is critical in
forming a stable RNA:NF-kB:IkBa complex.
Next, we compared the affinity of NK286–444 containing both
hairpins A and B with a consensus kB-binding DNA fragment
to bind p65 in EMSA competition assays. Addition of a RNA
probe containing NK286–444 at an RNA:DNA ratio of 1:1 efficiently
decreased the DNA:NF-kB complex, while a similar level of
competition could only be achieved by DNA probe at 5:1 ratio
Figure 5. NKILA Binds to p65 at Two
Different Sites
(A) The effects of wild-type or mutant NK286–444 on
the accessibility of amino acids in NF-kB p65,
determined by biotin-labeling assay (mass spectra
of NF-kB p65 with indicated treatments; numbers
indicate positions of amino acids; *biotin labeling
inhibited by RNA).
(B and C) MCF-7 cells were co-transfected with
siRNA targeting 30-UTR of endogenous p65 and
pcDNA3.1 vectors expressing wild-type or p65
mutants disrupting its interaction with hairpin A
(muta: R33A, R35A, Y36A, and E39A) or hairpin B
(mutb: K56A and K62A). (B) RNA-IP of GST-tag-
ged p65 (mean ± SD, n = 3, *p < 0.05 versus IgG).
(C) Sequential RNA-IP of IkBa and then GST-tag-
ged p65 (mean ± SD, n = 3, ***p < 0.001 versus
IgG).
See also Figure S5 and Table S5.(Figure S4E). Furthermore, it took 53 the amount of DNA probe
to compete NF-kB:NK286–444 complex to the level competed by
13 the non-labeled NK286–444 probe (Figure S4F). Therefore, the
affinity of NK286–444 containing both hairpins A and B to bind p65
is much stronger than consensus kB-binding DNA.
RNA footprinting assay identified two different sites in
NK286–444 that belong to hairpins A and B, respectively, and cor-
responding bands disappeared when binding to p65 or p65 and
IkBa (Figure S4G). Furthermore, mutation of hairpin A at nt 331
and its complementary nt 351 (NK286–444mA, NK322–359mA, and
NKmA, Table S4) abrogated the binding of RNA to NF-kB in the
presence or absence of IkBawithout disrupting the hairpin struc-
ture (Figures 4D and 4E and Figures S4C and S4H). How-
ever, probes with hairpin B mutated by deleting nt 403–409
(NK286–444mB and NKmB, Table S4) bind NF-kB alone but failed
to do so in the presence of IkBa (Figures 4D and 4E and Fig-
ure S4H). These data suggested that hairpin A is essential for
NKILA to bind p65 and hairpin B that also binds p65 prevents
the disruption of p65:NKILA complex by IkBa, so that a stable
NKILA:NF-kB:IkBa complex could be formed.
By analyzing differential accessibility of lysine residues in p65
to biotin with or without RNA engagement (Kvaratskhelia and Le
Grice, 2008), we identified the amino acids in p65 that physically
interact with RNA. The 2445 Da peptide (S51 to R73, Table S5A)
was biotinylated with the peak shifting to 2,897 Da (Table S5B),
which was substantially reduced by NK286–444 that contains
both hairpin A and B, but not by NK286–402 that contains only
hairpin A (Figure 5A), suggesting an interaction between
hairpin B and the peptide that is nine amino acids downstream
of the consensus DNA-binding sites (Chen et al., 1998; GhoshCancer Cell 27, 370–3et al., 2012). Moreover, mutation of
hairpin B (NK286–444mB) abrogated the
RNA/peptide interaction, whereas muta-
tion of hairpin A (NK286–444mA) disrupted
the essential RNA/p65 binding and thus
also abrogated the RNA/peptide interac-
tion (Figure 5A). Similar findings were
obtainedwhen full-length NKILAwithmu-
tation of hairpin A (NKmA) or B (NKmB) wasused (Figure S5A). On the other hand, point mutations at the
hairpin A (R33A, R35A, Y36A, and E39A) or the hairpin B-binding
site (K56A and K62A) of p65 disrupted its interaction with NKILA
in vivo, which was independent and dependent of IkBa binding,
respectively (Figures 5B and 5C).In contrast, although hairpin A
also binds to c-rel (Figure S4C), RNA footprinting assay demon-
strated that c-rel did not interact with the hairpin B of NK286–444
(Figure S5B). This is probably due to different amino acids in
the c-rel site corresponding to the hairpin B-binding site in p65
(STDTTKTHPTIKINGYTGPGTVR for p65 and STDNNRTYPSI
QIMNYYGKGKVR for c-rel). More importantly, in vitro RNA/pro-
tein interaction assay showed that NKILA can only retrieve c-rel
in the experiments without IkBa, whereas the presence of IkBa
abrogated the interaction between NKILA and c-rel (Figure S5C),
which is consistent with previous reports that IkBa can disso-
ciate DNA:NF-kB interaction (Zabel and Baeuerle, 1990). Collec-
tively, these data suggest that hairpin B binding to S51-R73 of
p65 is necessary for NKILA to stably associate with NF-kB:IkB
complex.
NKILA Directly Inhibits IkB Phosphorylation by Masking
the IKK Phosphorylating Sites
To explore how p65-bound NKILA inhibits IkB phosphorylation,
we used an in vitro kinase assay, in which purified active IKKb
was added to p65-prebound IkBa. The addition of NKILA into
p65-prebound IkBa prior to active IKKb prevented in vitro IkBa
phosphorylation, but adding NKILA after IKKb did not inhibit
IkBa phosphorylation (Figure 6A and Figure S6A), suggesting
that NKILA inhibits IKKb-induced IkBa phosphorylation, but
does not dephosphorylate IkBa. NKILA mutated at hairpin A81, March 9, 2015 ª2015 Elsevier Inc. 375
Figure 6. NKILA Directly Inhibits IkB Phosphorylation by Masking
the IKK Phosphorylating Sites
(A) In vitro phosphorylation assay showing the effects of NKILA on IKK-
mediated IkBa phosphorylation. inhib, inhibitor; D, DMSO; B, Bay-117082; W,
Wedelolactone; +*, IKKbwas added to reaction mixture 20 min prior to NKILA;
NKmA, mutation of hairpin A in NKILA; NKmB, mutation of hairpin B in NKILA.
(B) The effects of NKILA on the accessibility of amino acids in IkBa to IKK,
determined by biotin-labeling assay followed by mass spectrometry (mass
spectra of IkBa with indicated treatment were shown. Numbers indicate the
position of amino acids. *Assay in which biotin labeling was inhibited by
respective RNA.
(C and D) Inhibition of in vitro IkBa phosphorylation by NKILA and its
sequentially deleted mutants (C), or NKmC mutant (D). NKmC, NKILA mutant
deleting the hairpin C.
(E) The ability of NKILAmutants to inhibit TNF-a-induced IkBa phosphorylation
in MDA-MB-231 cells.
See also Figure S6 and Table S6 and Table S7.(NKmA) or B (NKmB) that fails to interact with p65:IkBa complex
did not inhibit the IKKb-induced IkBa phosphorylation (Figure 6A
and Figure S6A), indicating that binding with the p65:IkBa com-
plex is prerequisite for NKILA to inhibit the IKKb-induced IkBa
phosphorylation.
Mass spectrum analysis for trypsin-digested peptides from
IkBa revealed that a peptide peak from free IkBa (L25 to K47,
Figure 6B and Table S6A) that harbors both of the IKKb-medi-
ated phosphorylation sites (S32 and S36) was biotinylated and
shifted (Table S6B). Importantly, the biotinylation of this peak
was substantially reduced in the presence of p65-bound NKILA376 Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc.(Figure 6B), suggesting a close contact between NKILA and
phosphorylation sites of IkBa that leads to reduced IKKb acces-
sibility to its target sites on IkBa. Thus, NKILA inhibits IKKb-in-
duced IkBa phosphorylation by physically masking the phos-
phorylation sites of IkBa and blocking its accessibility to IKK.
Further, NKILA deletion to nt 1,300 from its 30-end preserved
its ability to inhibit IkBa phosphorylation, but deletion to nt
1,100 abrogated such effect (Figure 6C), suggesting that nt
1,100–1,300 are critical to its suppressive function on IkBa phos-
phorylation. Moreover, Mfold and RNAfold (Figure S6B) pre-
dicted a triple-loop hairpin structure at nt 1,121–1,216 of NKILA
(hairpin C), as further verified by RNA structure probing (Fig-
ure S6C). To confirm if hairpin C directly interact with IkBa,
NKILA was incubated with p65 and p50 in the presence or
absence of IkBa and the RNA-protein complex was subjected
to RNase T1 digestion and PCR amplification. A qRT-PCRbased
RNA protection assay demonstrated that the region from nt
1,135 to 1,195, which resides within hairpin C (nt 1,121–1,216),
was enriched when IkBa was incubated with the complex, indi-
cating a direct interaction between hairpin C and IkBa (Fig-
ure S6D and Table S7). Although mutation to disrupt hairpin C
in NKILA (NKmC, Table S4) did not reduce its binding to p65 (Fig-
ure S6E), NKmC failed to mask the phosphorylation motif on IkBa
(Figure S6F) and thus could not inhibit the IKKb-induced IkBa
phosphorylation in vitro (Figure 6D). These observations indicate
that nt 1,121–1,216 is necessary for NKILA to physically interact
and mask the phosphorylation motif of IkBa.
NKILA with mutation at each of the hairpins (NKmA, NKmB,
NKmC) all failed to inhibit IkBa phosphorylation and NF-kB acti-
vation in MDA-MB-231 cells (Figure 6E and Figure S6G), indi-
cating that all three hairpins are essential for NKILA function.
On the other hand, replacement of endogenous wild-type p65
or IkBa with their mutants, by RNAi-targeting the 30UTR of
endogenous gene and ectopic expression of p65 or IkBa mu-
tants that failed to interact with NKILA, abrogated the effect of
NKILA to inhibit NF-kB activity in MCF7 cells (Figures S6H and
S6I). Taken together, hairpins A, B, and C of NKILA play different
roles to bind p65, assist the formation of the NF-kB:IkBa:NKILA
complex and mask phosphorylation sites of IkBa, respectively,
which coordinately inhibit IkBa phosphorylation.
NKILA Inhibits NF-kB-Mediated Breast Cancer
Metastasis
Aberrant NF-kB signaling can promote tumorigenesis by inhibit-
ing apoptosis (Baldwin, 2012) and increasing invasion (Huber
et al., 2004). Consistent with its anti-NF-kB role, NKILA
increased apoptosis and reduced invasion in MDA-MB-231 cells
(Figures 7A and 7B). Conversely, silencing NKILA in MCF7 cells
reduced apoptosis and enhanced invasiveness (Figures 7A and
7B), suggesting that NKILA antagonizes the anti-apoptotic and
pro-invasive effects of NF-kB. However, in the presence of sc-
3060 or JSH-23 that abrogates NF-kB nuclear translocation,
NKILA could not further increase apoptosis or reduce invasion
in MDA-MB-231 cells (Figures 7A and 7B), suggesting that
NKILA exerts its effect via inhibiting NF-kB. Further, breast can-
cer cell invasion was not enhanced by silencing NKILA when an
IKK-resistant TD-IkBa was expressed (Figure S7A), and was not
inhibited by NKILA when IkBa was silenced (Figure S7B), indi-
cating that the effects of NKILA are dependent on IkBa.
Figure 7. NKILA Inhibits NF-kB-Mediated
Breast Cancer Metastasis
(A and B) Apoptosis (A) and invasion (B) of MDA-
MB-231 or MCF7 cells stably expressing anti-
sense, wild-type or mutant NKILA, or expressing
shRNA targeting NKILA, assayed by Annexin-V/PI
staining (48 hr after seeding) and Boyden Cham-
ber assay (8 hr for MDA-MB-231 and 16 hr for
MCF7 after seeding, respectively). 3060, 10 mM
sc-3060; JSH, 5 mM JSH-23; mean ± SD; n = 3;
**p < 0.01 versus vec; #p < 0.05 versus shvec;
###p < 0.001 versus shvec.
(C) In situ hybridization (ISH) staining for NKILA
(upper; the percentage of positive cells is indi-
cated under the picture, mean ± SD, n = 3) and
luminal imaging for NF-kB activities (lower; the
photon intensities are indicated under the picture
[3108, mean ± SD, n = 3]) in xenografts of MDA-
MB-231 stably expressing NKILA or MCF7 stably
expressing NKILA-shRNA bearing a kB-depen-
dent luciferase reporter construct showing NF-kB
activity.
(D) Luminal imaging for lung, liver, and lymph node
(LN) metastasis of MDA-MB-231 or MCF7 xeno-
grafts stably expressing NKILA or NKILA-shRNA.
The metastasis was observed when primary tu-
mors grew to similar size (1.5 cm in diameter when
sacrificed to examine metastasis). The photon in-
tensities in the organ are indicated (3106, mean ±
SD, n = 3).
(E) qRT-PCR for hHPRT mRNA normalized to
GADPH mRNA in the lungs and livers of mice or-
thotopically implanted with MDA-MB-231 or
MCF7 cells (mean ± SD, n = 8, ***p < 0.001 versus
vec, ###p < 0.001 versus shGFP).
(F) Kaplan-Meier survival curve of mice ortho-
topically implanted with MDA-MB-231 or MCF7
cells (n = 8 per group).
See also Figure S7.In xenografts of breast cancer cell lines, NKILA expression in
low-metastatic MCF7 xenografts was much higher than that in
high-metastatic MBA-MD-231 xenografts, which was negatively
correlated with their NF-kB activities (Figure 7C). Ectopic NKILA
expression inMBA-MD-231 xenografts reduced NF-kB activities
(Figure 7C), inhibited cancer metastasis to the lungs, liver, and
lymph nodes (Figures 7D and 7E and Figure S7C), and prolonged
mice survival (Figure 7F). Conversely, silencing NKILA in MCF7
xenografts increased their NF-kB activities (Figure 7C) and
significantly promoted cancer metastasis (Figures 7D and 7E
and Figure S7C) and reduced mice survival (Figure 7F). Taken
together, these results indicate that NKILA inhibits breast cancer
metastasis by suppressing NF-kB activation.
NKILA Reduction Predicts Poor Clinical Outcome
in Patients with Breast Cancer
To further evaluate the clinical significance of NKILA in breast
cancer progression, we used in situ hybridization to examineCancer Cell 27, 370–3NKILA expression in 124 cases of benign
breast tissues, 81 ductal carcinomas
in situ (DCIS) and 942 invasive ductal car-
cinomas (IDC) of the breast. AbundantNKILA expression was observed in the epithelia of normal breast
tissues and DCIS that are localized within the basement mem-
brane (Figure 8A and Figure S8A). In comparison, NKILA expres-
sion was obviously lower in the invasive carcinomas without
distal or regional lymph node metastasis, and further reduced
in those with metastasis (Figure 8A and Figure S8A). In contrast,
the pattern of miR-103 and miR-107 expression was opposite to
that of NKILA in normal and malignant breast tissues (Figure 8A)
and a negative correlation was observed betweenNKILA and the
miRNA expression in the invasive breast cancers (p < 0.001, Fig-
ure S8B). This was further quantified by qRT-PCR showing that
NKILA in normal breast tissues was comparable to DCIS (p >
0.05), but was approximately 6.6-fold higher than the IDCs
without metastasis (p < 0.001) and approximately 19.7-fold
higher than those with metastasis (p < 0.001, Figure 8B). Like-
wise, qRT-PCR also revealed that NKILA was negatively cor-
related with miR-103 (p < 0.001) and miR-107 (p < 0.001, Fig-
ure S8C). These data suggest that reduced NKILA expression81, March 9, 2015 ª2015 Elsevier Inc. 377
Figure 8. Low NKILA Expression Predicts Poor Clinical Outcome in
Patients with Breast Cancer
(A) ISH for NKILA, miR-103, and miR-107 in paraffin-embedded tissue of
normal breast, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma
(IDC) with and without metastasis.
(B) The expression of NKILA, normalized to GAPDH, in fresh-frozen samples,
determined by qRT-PCR.
(C) Kaplan-Meier survival curve of patients with breast cancer with low
(staining index, [SI]% 3, n = 529) and high NKILA (SI > 3, n = 494; p < 0.001)
with a median follow-up period of 40 months.
(D) NKILA expressions (NB, Northern blotting) and basal NF-kBactivity (EMSA)
in primary normal breast epithelial cells and primary breast cancer cells with or
without metastasis (met()/met(+); nos. 1, 2, 3 represent different individuals).
(E) NF-kB of normal primary breast cells transfected with indicated siRNAs,
examined by EMSA (GFP-si, GFPsiRNA; NK-si1, 2, NKILA siRNA1, 2).
See also Figure S8 and Table S8.is associated with clinical invasion and metastasis of breast
cancer.
We next correlated NKILA expression with the clinicopatho-
logical status of patients with breast cancers (Table S8A). In
addition to the association with lymph node (p < 0.001) and distal
metastasis (p < 0.001), reduced NKILA in breast cancer cells was
also correlatedwith advanced disease staging (p < 0.001), higher
histopathological grading (p < 0.001), and larger tumor (p <
0.001). However, there was no observed difference in NKILA
expression regarding ER status, as well as Ki67 and PCNA
expression (p > 0.05). More importantly, NKILA reduction was
associated with poor patient survival (p < 0.001, Figure 8C),378 Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc.and could serve as an independent prognostic factor for breast
cancers in a multivariate Cox regression analysis (p = 0.002,
Table S8B).
To confirm the correlation of NKILA expression and NF-kB ac-
tivities identified in breast cancer cell lines, we isolated primary
breast epithelial cells from three cases of normal breast tissues,
three cases of invasive breast cancers without metastasis and
three cases with metastasis. Northern blot analysis demon-
strated that NKILA expression was abundant in normal breast
epithelial cells, but was obviously lower in invasive cancer cells
from breast tumors without metastasis and further reduced in
those with metastasis (Figure 8D). In agreement with findings
of the cell lines, basal NF-kB activities in these cells, determined
by EMSA, were negatively correlated with NKILA expression, as
lowest NF-kB activities were observed in normal breast epithelial
cells and highest in breast cancer cells from patients with metas-
tasis (Figure 8D). More importantly, silencing NKILA in normal
breast epithelial cells dramatically elevated NF-kB activities (Fig-
ure 8E), suggesting that NKILA is essential to prevent aberrant
NF-kB activation even under normal physiological conditions.
In addition, NKILAwas upregulated by the inflammatory cytokine
TNF-a, not only in breast cancer cells with or without metastasis,
but also in normal breast epithelial cells determined by qRT-PCR
(Figure S8D) and FISH assay (Figure S8E), suggesting that the
negative feedback loop of NF-kB mediated by NKILA generally
exists in normal andmalignant breast epithelia. Finally, we exam-
ined the expression of NKILA in normal and cancer tissues of
prostate, colon, lung, and liver in addition to breast. The results
showed that NKILA was abundantly expressed in normal pros-
tate, colon, and lung tissue, but its expression was much lower
in normal liver tissue. Similar to the breast, NKILA expression
was reduced in cancer versus normal tissues across tissue types
(Figure S8F).
DISCUSSION
NF-kB is constitutively active in many tumors and considered to
be a key factor in cancer development (DiDonato et al., 2012;
Fornier et al., 2007). A number of negative regulators for NF-kB
pathway, for example deubiquitinase (DUB) A20 (Cake et al.,
2003) and CYLD (Brummelkamp et al., 2003), ubiquitin ligase
SOCS-1 (Ruland, 2011), and a group of miRNAs (Boldin and Bal-
timore, 2012), etc, have been shown to be tumor suppressors.
Many of these regulators are transcribed by NF-kB, but partici-
pate in the negative feedback loops to prevent sustained or
excessive activation of NF-kBpathway (Ruland, 2011).We found
that NKILA, a NF-kB-induced lncRNA, is also involved in the
negative feedback loop of NF-kB regulation, and serves as a tu-
mor suppressor by inhibiting breast cancer progression and
metastasis. Different frommost previously identified NF-kB sup-
pressors that either inhibit signaling upstream of IKK complex or
affect the amount of NF-kB or IkB (Ruland, 2011; Tse et al.,
2007), NKILA operates at the level of IkB by directly inhibiting
IKK-induced IkB phosphorylation without influencing IKK activ-
ity, which represents a different layer of negative regulation on
NF-kB pathway.
Only a fraction of malignancies with aberrant NF-kB activities
harbors gene mutations that affect components of NF-kB
pathway and activate NF-kB. Constitutive NF-kB activation in
the malignant cells of many solid tumors was thought to be
mainly driven by inflammatory cytokines in the tumor microenvi-
ronment (DiDonato et al., 2012; Fornier et al., 2007). Herein, our
data indicate that NKILA is capable of restraining NF-kB activity
in both normal and malignant breast epithelial cells, while its
downregulation leads to aberrant NF-kB activation even without
inflammatory stimulation, suggesting that NKILA is an essential
‘‘gatekeeper’’ of NF-kB signaling in resting cells. In normal breast
epithelia or non-invasive breast cancers, NKILA is abundantly
expressed and silencing its expression results in appreciable
phosphorylation and degradation of IkB, probably mediated by
the basal activity of IKK. Indeed, previous studies demonstrated
that basal IKK activity was critical and sufficient to degrade NF-
kB-bound IkB and may lead to NF-kB activation when synthesis
of IkB molecules was suppressed (Ghosh and Dasgupta, 1996;
O’Dea et al., 2008). Therefore, our findings suggest that stable
NF-kB-bound IkB that maintains normal NF-kB activity in resting
cells depends not only on IkB replenishment (Ghosh and
Dasgupta, 1996) but also on NKILA-mediated protection of
NF-kB-bound IkB from being phosphorylated by basal active
IKK (Figure S8G). However, in invasive cancer cells, NKILA is
significantly reduced by miR-103/107-mediated degradation,
which results in abnormal NF-kB activation and thus contributes
to cancer metastasis and poor patient outcome (Figure S8H).
Moreover, because NF-kB signaling plays a pivotal role in
many physiological and pathological processes, the importance
of NKILA-mediated regulation on NF-kB activation is not limited
to cancer progression and metastasis, but it may also underlie
the process of embryo and tissue development, immune and
stress responses, inflammation and other diseases related to
NF-kB activation (Ghosh and Dasgupta, 1996).
Our findings reveal that a stable NKILA:NF-kB:IkBa complex in
the cytoplasm is prerequisite for NKILA to prevent IKK-induced
IkB phosphorylation. However, it has been well established
that stable DNA:NF-kB:IkBa complexes are unlikely to form
because IkBa actively destabilizes and disrupts the complex of
NF-kB and its cognate DNA. In agreement, our results also
show that the 322–359 fragment of NKILA that contains only
hairpin A, a mimic of the kB DNA motif, is rapidly dissociated
from p65 by IkBa. However, with the aid of a neighboring hairpin
B that binds to the amino acid residues of p65 in the vicinity of its
consensus DNA binding site, hairpin A is no longer dissociated
and a stable RNA:NF-kB:IkBa complex is formed. The crystal
structure of the NF-kB:IkBa complex has documented that the
presence of IkBa leads to en blocmovement and conformational
change of the p65 subunit amino-terminal domain mainly due to
electrostatic interaction. This switches the p65 subunit from a
DNA-bound ‘‘open’’ to a ‘‘closed’’ conformation, and thus in-
duces allosteric inhibition of NF-kB DNA binding. Nevertheless,
a recent study detects a transient complex of NF-kB and IkBa
with DNA upon stepwise addition of a kB binding DNA fragment
to the NF-kB:IkBa complex, suggesting that the DNA binding
site of p65 is not totally blocked by IkBa (Sue et al., 2011).
Here, our present findings indicate that additional binding of
NKILA hairpin B to the amino acids vicinal to the consensus
DNA binding motif of p65 not only enhances the affinity of NKILA
to p65, but also abolishes IkBa-mediated inhibition of NKILA/NF-
kB interaction and plays an essential role in forming a stable
NKILA:NF-kB:IkBa complex. In fact, the amino acids that bindNKILA hairpin B locate at loop L1 of the p65 N-terminal domain,
while two affinity- and specificity-determining DNA-binding res-
idues of p65, Arg-33 and Arg-35, are from this same loop. There-
fore, this additional binding may help to stabilize the interaction
between NKILA hairpin A and p65 amino-terminal domain
against the electrostatic attraction by IkBa. On the other hand,
although c-rel has been shown to bind a large variety of target
DNA sequences, it bears variation in the amino acids at the
hairpin B binding site and therefore cannot bind hairpin B.
Consequently, c-rel alone is able to bind NKILA, but cannot
form a stable complex with NKILA in the presence of IkBa.
Therefore, our findings may provide an exceptional example
for nucleic acids to bind the NF-kB:IkB complex and suggest
that the flexible and versatile secondary structure of lncRNA
may extend their capability to interact with protein complexes.
In addition to the two adjacent hairpins A and B that act in con-
cert for the formation of a stable NKILA:NF-kB:IkBa complex,
NKILA activity also depends on a discrete triple-loop hairpin C
that physically interacts with IkB and masks its phosphorylation
sites (Figure S8I). Although serving as molecular scaffolds that
interact withmultiple regulatory proteins is one of themajor func-
tions for many lncRNAs (Guttman and Rinn, 2012), NKILA differs
from these scaffold lncRNAs by directly regulating signal trans-
duction without mobilizing other regulatory proteins. A scaffold
lncRNA assembles other regulatory proteins to form a unique
functional complex and the protein components could not form
a complex without the lncRNA. In addition, the scaffold lncRNA
itself does not carry out any regulatory effect, but relies on the re-
cruited proteins to function. For example, it was shown that
NRON was reported as a molecular scaffold that is necessary
for the assembly of NFAT and several NFAT kinases, including
CK1, GSK3b, and DYRK2, which are responsible for NFAT phos-
phorylation and its sequestration in the cytosol (Sharma et al.,
2011). NRON depends on their interacting proteins to carry out
the function. In contrast, formation of the NF-kB:IkB complex
does not depend on NKILA, suggesting the lncRNA does not
act as a scaffold to assemble NF-kB and IkB. Furthermore,
p65-bound NKILA inhibits IKK-induced IkB phosphorylation by
directly masking the phosphorylation sites of IkB from IKK,
revealing a underappreciated function of lncRNAs that regulate
signal transduction by directly acting on active domains of
signaling proteins without mobilizing other regulatory molecules.
Align with our findings, another cytoplasmic lncRNA, lnc-DC,
directly blocks STAT3 phosphorylation by SHP1 and inhibits
STAT3 activation (Wang et al., 2014). Therefore, our data and
others may indicate the existence of a class of lncRNAs that
regulate signal transduction at post-translational level, and our
present study has further illustrated the in-depth mechanisms
how these lncRNAs interact with the signaling proteins.
Finally, our findings have therapeutic implications. It has long
been acknowledged that RNA is a malleable evolutionary sub-
strate compared with protein, and mutation or deletion of the re-
gions outside its functional domains may not interfere with its
core functionality (Wutz et al., 2002). Therefore, synthetically en-
gineered ncRNAs containing the functional domains that act on
the active regions of signaling proteins can be tested for their
therapeutic effects on diseases with aberrant activation of major
signaling pathways, which may thus offer a category of RNA
therapy.Cancer Cell 27, 370–381, March 9, 2015 ª2015 Elsevier Inc. 379
EXPERIMENTAL PROCEDURES
RNAI Immunoprecipitation, RNA Pulldown, and RNA EMSA
RNA immunoprecipitation was performed using Magna RIP RNA-Binding Pro-
tein Immunoprecipitation Kit (17-700, Millipore) according to manufacturer’s in-
structions. RNA for in vitro experimentswas transcribed using T7HighYieldRNA
Synthesis Kit (E2040S, NEB) according to manufacturer’s instructions. The 30-
end biotin-labeled RNA probes used in RNA pulldown and RNA EMSA were
generated using RNA 30 End Biotinylation Kit (20160, Pierce) according to man-
ufacturer’s instructions. RNA pulldown was performed as described (Tsai et al.,
2010). Five picomoles of 30-biotinylated RNA was used in each pulldown assay.
RNA EMSA was performed using LightShift Chemiluminescent RNA EMSA Kit
(20158, Pierce) according to manufacturer’s instructions. To be specific, RNA
samples used in RNA EMSAwere re-natured in 13RNAEMSAbuffer by heating
to 95C for 3 min, placed on ice for 5 min, and placed at room temperature for
20min. Detection of biotinylated RNA in blots were performed using Chemilumi-
nescent Nucleic Acid Detection Module Kit (89880, Pierce).
In Vitro Phosphorylation Assay
Briefly, GST-labeled recombinant human IKKb was purified in SF9 insect cells.
Recombinanthuman IkBa (ab113133)waspurchased fromAbcam. In vitrophos-
phorylation was performed in 13 kinase buffer (25 mM Tris-HCl pH 7.5, 10 mM
MgCl2, 0.1 mMNa3VO4, 5 mM b-glycerophosphate, and 2 mMDTT). Phosphor-
ylation of IkBawas detected by immunoblotting or ELISA using PathScan Phos-
pho-IkBa (Ser32) Sandwich ELISA Kit (#7355, Cell Signaling Technology).
Structural Analysis of Protein-RNA Interactions with Biotin-Labeling
Assay and Mass Spectrometry
Biotin-labeling assay was performed as described elsewhere (Kvaratskhelia
and Le Grice, 2008). Briefly, RNA and the indicated proteins were added into
RIP buffer and incubated for 30 min, followed by adding of 400 mMNHS-biotin
(20217, Pierce) with 20 min incubation. Proteins were then separated by SDS-
PAGE and in-gel proteolysis was performed using trypsin (89871, Pierce).
Mass-spectrum analysis was then performed on MALDI-TOF (Bruker Dalton-
ics) as described elsewhere (Kvaratskhelia and Le Grice, 2008).
Tumor Xenografts
Six-week-old female athymic nude mice were purchased from Vital River Lab-
oratories, housed under standard conditions at the animal care facility at Cen-
ter of Experimental Animal of Sun Yat-sen University. The procedures were
approved by SunYat-sen University Animal Care and Use Committee.
Patients and Tumor Specimens
Paraffin-embedded samples of normal breast tissue and carcinomas were ob-
tained from 1,147 patients (normal 124, cancer 1,023) in the breast tumor cen-
ter, Sun Yat-sen Memorial Hospital, Sun Yat-sen University from February
2006 to October 2012. Fresh tumor tissues were obtained from 84 breast can-
cer cases (DCIS 12, IDC 72) before any treatment during the surgery. Fresh
normal breast tissue was from samples from breast reduction surgery (eight
cases) or quadrantectomy (16 cases). All samples were collected with signed
informed consent according to the internal review and ethics boards of Sun
Yat-sen Memorial Hospital.
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